Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Serina Therapeutics (SER) over the last 8 years, with Q2 2025 value amounting to 4280.77%.

  • Serina Therapeutics' EBITDA Margin rose 32996200.0% to 4280.77% in Q2 2025 from the same period last year, while for Sep 2025 it was 18595.69%, marking a year-over-year decrease of 184520100.0%. This contributed to the annual value of 30442.86% for FY2024, which is 303436200.0% down from last year.
  • Serina Therapeutics' EBITDA Margin amounted to 4280.77% in Q2 2025, which was up 32996200.0% from 39635.71% recorded in Q4 2024.
  • Serina Therapeutics' 5-year EBITDA Margin high stood at 39635.71% for Q4 2024, and its period low was 46420.0% during Q1 2024.
  • Over the past 5 years, Serina Therapeutics' median EBITDA Margin value was 6914.81% (recorded in 2021), while the average stood at 8698.11%.
  • Data for Serina Therapeutics' EBITDA Margin shows a peak YoY increase of 396279100bps (in 2024) and a maximum YoY decrease of -432133300bps (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Serina Therapeutics' EBITDA Margin stood at 6914.81% in 2021, then tumbled by -222bps to 22275.0% in 2022, then soared by 100bps to 7.81% in 2023, then soared by 507599bps to 39635.71% in 2024, then plummeted by -111bps to 4280.77% in 2025.
  • Its EBITDA Margin stands at 4280.77% for Q2 2025, versus 39635.71% for Q4 2024 and 10071.43% for Q3 2024.